DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer
- 1.8k Downloads
Colorectal cancer (CRC) is the third most common type of cancer and is responsible for 9 % of cancer deaths in both men and women in the USA for 2013. It is a heterogenous disease, and its three classification types are microsatellite instability, chromosomal instability, and CpG island methylator phenotype. Biomarkers are molecules, which can be used as indicators of cancer. They have the potential to achieve great sensitivities and specificities in diagnosis and prognosis of CRC. DNA methylation biomarkers are epigenetic markers, more specifically genes that become silenced after aberrant methylation of their promoter in CRC. Some methylation biomarkers like SEPT9 (ColoVantage®) and vimentin (ColoSureTM) are already commercially available. Other blood and fecal-based biomarkers are currently under investigation and clinical studies so that they can be used in the near future. Biomarker panels are also currently being studied since they show great potential in diagnosis as they can combine robust biomarkers to achieve even greater sensitivities than single markers. Finally, methylation-sensitive microRNAs (miRNAs) are very promising markers, and their investigation as biomarkers, is only at primitive stage.
KeywordsDNA methylation Biomarkers Colorectal cancer CIMP CIN MSI
Conflict of interest
All authors state that they have no conflicts of interest.
- 6.Derks S, van Engeland M (2012) Promoter CpG island methylation in colorectal cancer. In: Appasani K (ed) Epigenomics: from chromatin biology to therapeutics, 1st edn. Cambridge University Press, Cambridge, pp 307–308Google Scholar
- 7.Philips T (2008) The role of methylation in gene expression. Nat Edu 1:127Google Scholar
- 13.Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM et al (2007) The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132:127–138PubMedCrossRefGoogle Scholar
- 20.Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS (2007) CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 450:529–537PubMedCrossRefGoogle Scholar
- 27.Derks S, Postma C, Carvalho B, van den Bosch SM, Moerkerk PT, Herman JG, Weijenberg MP, de Bruïne AP, Meijer GA, van Engeland M (2008) Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis 29:434–439PubMedCrossRefGoogle Scholar
- 29.Tóth K, Sipos F, Kalmar A, Patai AV, Wichmann B, Stoehr R, Golcher H, Scheller V, Tulassay Z, Molnár B (2012) Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS One 7(11):e48547. doi: 10.1371/journal.pone.0046000 PubMedCrossRefGoogle Scholar
- 32.Nishio M, Sakakura C, Nagata T, Komiyama S, Miyashita A, Hamada T, Kuryu Y, Ikoma H, Kubota T, Kimura A et al (2010) RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Res 30:2673–2682PubMedGoogle Scholar
- 35.Melotte V, Lentjes MHFM, van den Bosch SM, Hellenbrekers DMEI, de Hoon JPJ, Wouters KAD, Daenen KLJ, Partouns-Hendriks IEJM, Stressels F, Louwagie J et al (2009) N-myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 101:916–927PubMedCrossRefGoogle Scholar
- 54.Rawson JB, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, Younghusband HB, Parfrey PS, Young JP, Pollett A, Green RC et al (2011) Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients. Br J Cancer 104:1906–1912PubMedCrossRefGoogle Scholar